RxDoctor Payments Data

Sarmistha Bhalla, MD

Psychiatry · Mexico, MONPI 1083791792

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 75 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$320
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$319
  • Validus Pharmaceuticals LLC$310
  • Neurocrine Biosciences, Inc.$301
  • AbbVie$232
  • Teva Pharmaceuticals USA, Inc.$226
  • plus $527 from 8 others

What the payments were for

  • Food & beverage$2,13596%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,235 in reported general payments places this provider in the 75th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$7,743
Medicare patients
35
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate26$269,934
IngrezzaValbenazine Tosylate23$188,926
Austedo XrDeutetrabenazine14$112,039
Invega SustennaPaliperidone Palmitate12$43,282
RexultiBrexpiprazole22$29,933
AristadaAripiprazole Lauroxil11$29,048
Clozapine289$24,445
Paliperidone ErPaliperidone33$14,243
Divalproex Sodium240$13,879
Aripiprazole99$7,923
Chlorpromazine Hcl30$5,898
XareltoRivaroxaban20$5,340
Haloperidol Decanoate80$4,868
Carbamazepine67$4,752
Ziprasidone Hcl29$3,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Xarelto$31$318,55658 claims
Neurocrine Biosciences, Inc.Ingrezza$301$188,92623 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine$226$113,29145 claims
Otsuka America Pharmaceutical, Inc.Rexulti$128$29,93322 claims
Alkermes, Inc.Aristada$320$29,04811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Mexico

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →